Active

Newton Biocapital I, pricaf privée de droit belge

Switched

BE0674831275

Rechtspersoon Public limited company 1 establishment

Tervurenlaan 273, 1150 Sint-Pieters-Woluwe

Active for

9 year, 4 months

Financials

Financial year 2025

Worth noting

  • A loss two years in a row.

Gross margin

€ -1.4 million

▲ 21% vs 2024

Profit

Caution

€ -5.3 million

▲ 72% vs 2024

Debts

Low

€ 45,683

▼ 41% vs 2024

Newton Biocapital I, pricaf privée de droit belge from Sint-Pieters-Woluwe, company number BE0674831275, closed financial year 2025 with a result of € -5.3 million after tax. For that financial year Newton Biocapital I, pricaf privée de droit belge recorded a gross margin of € -1.4 million and equity of € 59.5 million. Compared with financial year 2024, the result moved from € -18.7 million to € -5.3 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 1, 2026.

What happened at Newton Biocapital I, pricaf privée de droit belge?

What happened at Newton Biocapital I, pricaf privée de droit belge in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • JCO CONSULTING SRL stepped down as director. NBB
  • DAB MANAGEMENT SRL stepped down as director. NBB
  • SPARAXIS SA stepped down as director. NBB
  • Michihiko WADA stepped down as director. NBB
  • SUNATHIM SRL stepped down as director. NBB
  • SFPIM SA DP stepped down as director. NBB
  • New annual accounts for financial year 2025: loss of € 5.3 million. Source: NBB ↗
  • Christophe DEMAIN stepped down as director. NBB

In short

From € 3.8 million loss in 2021 to € 5.3 million loss in 2025.

Best year ever: 2023, with € 909,317 profit.

Original PDFs at the National Bank ↗

A new publication or filing at Newton Biocapital I, pricaf privée de droit belge? We notify you, reason included.

Follow Newton Biocapital I, pricaf privée de droit belge

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

NEWTON BIOCAPITAL PARTNERS SRL
Newton Biocapital I, pricaf privée de droit belge
DEUTERONCOLOGY 69.6%
DIM3 - En liquidation 36.2%
PRISM BIOLAB 30.3%
ABOLERIS HOLDCO 25.7%
+7

Behind Newton Biocapital I, pricaf privée de droit belge is NEWTON BIOCAPITAL PARTNERS SRL. It owns 69.6% of DEUTERONCOLOGY, 36.2% of DIM3 - En liquidation, 30.3% of PRISM BIOLAB, 25.7% of ABOLERIS HOLDCO, 25.5% of NEUVASQ BIOTECHNOLOGIES and 24.4% of EPICS THERAPEUTICS itself.

See the full network in the app

Directors

According to the 2025 annual accounts

NEWTON BIOCAPITAL PARTNERS SRL

Personne déléguée à la gestion journalière · represented by Alain PARTHOENS

Also active at: SYNERGIA MEDICAL, Newton Biocapital I Investment Pool, EPICS THERAPEUTICS +4 more

since 2017

JCO CONSULTING SRL

Director · represented by Jean Combalbert

Also active at: EPICS THERAPEUTICS, THERAtRAME

since 2025 · until 2027

DAB MANAGEMENT SRL

Director · represented by Dirk BOOGMANS

Also active at: C.S.M., ENERGY SOLUTIONS GROUP, Smile Invest Management Company +3 more

since 2024 · until 2027

SPARAXIS SA

Director · represented by Sophie SAUVAGE

Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International +228 more

since 2024 · until 2027

Michihiko WADA

Director

since 2024 · until 2027

SUNATHIM SRL

Director · represented by Ajit SHETTY

Also active at: SOUDAL HOLDING, reMYND, REJUVENATE BIOMED +1 more

since 2024 · until 2027

Christophe DEMAIN

Director

since 2021 · until 2025

SFPIM SA DP

Director · represented by François FONTAINE

Also active at: Aviapartner Belgium, Société Anonyme Belge de Constructions Aéronautiques, Société Nationale de Construction Aérospatiale +62 more

since 2024 · until 2027

Robert HIRST

Director

since 2024 · until 2025

Establishments

Establishment units

Physical locations of this company

Registered office

Tervurenlaan 273

1150 Sint-Pieters-Woluwe

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.

BELGIAN RISK MANAGEMENT ASSOCIATION

European Coil Coating Association

€ 877,191 revenue · 2025

FEDERATION EUROPEENNE DE RISK MANAGEMENT - FEDERATION OF EUROPEAN RISK MANAGEMENT ASSOCIATIONS

€ 3.2 million revenue · 2024

LATOUR & PETIT

€ 1.5 million gross margin · 2025

AQ PARTNERS

€ 69,850 gross margin · 2025

+16 more

Details

Company number
0674.831.275
VAT number
BE 0674.831.275
Registered office
Tervurenlaan 273, 1150 Sint-Pieters-Woluwe
Names & denominations
Newton Biocapital I, pricaf privée de droit belge
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
25 April 2017
Peppol
Active · Active since 27 Mar 2026
View on CBE Public ↗ Annual accounts (NBB) ↗

Frequently asked questions

What is the enterprise number of Newton Biocapital I, pricaf privée de droit belge?
The enterprise number of Newton Biocapital I, pricaf privée de droit belge is BE0674831275.
What is the address of Newton Biocapital I, pricaf privée de droit belge?
The registered office of Newton Biocapital I, pricaf privée de droit belge is located at Tervurenlaan 273, 1150 Sint-Pieters-Woluwe.
When was Newton Biocapital I, pricaf privée de droit belge founded?
Newton Biocapital I, pricaf privée de droit belge was founded on 25 April 2017.
Does Newton Biocapital I, pricaf privée de droit belge have a website?
No website is currently known for Newton Biocapital I, pricaf privée de droit belge.
How much profit did Newton Biocapital I, pricaf privée de droit belge make in 2025?
Newton Biocapital I, pricaf privée de droit belge recorded a loss after taxes of € 5,322,668 in financial year 2025.
What is the revenue of Newton Biocapital I, pricaf privée de droit belge?
As a small company, Newton Biocapital I, pricaf privée de droit belge is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -1,431,228.
Where can I find the annual accounts of Newton Biocapital I, pricaf privée de droit belge?
Newton Biocapital I, pricaf privée de droit belge files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of Newton Biocapital I, pricaf privée de droit belge?
According to the 2025 annual accounts, the directors of Newton Biocapital I, pricaf privée de droit belge are: NEWTON BIOCAPITAL PARTNERS SRL, JCO CONSULTING SRL, DAB MANAGEMENT SRL, SPARAXIS SA, Michihiko WADA, SUNATHIM SRL, Christophe DEMAIN, SFPIM SA DP.
Who owns Newton Biocapital I, pricaf privée de droit belge?
Behind Newton Biocapital I, pricaf privée de droit belge is NEWTON BIOCAPITAL PARTNERS SRL. It owns 69.6% of DEUTERONCOLOGY, 36.2% of DIM3 - En liquidation, 30.3% of PRISM BIOLAB, 25.7% of ABOLERIS HOLDCO, 25.5% of NEUVASQ BIOTECHNOLOGIES and 24.4% of EPICS THERAPEUTICS itself.